News & Media

DiaMedica’s DM-204 for Type 2 Diabetes Significantly Lowers Blood Glucose, Blood Pressure and Cholesterol Levels

DiaMedica Inc. (TSX-V: DMA) is pleased to announce the presentation of new compelling Type 2 diabetes data from studies of DM-204 at the Windhover Therapeutic Area Partnership Conference in Boston, MA, USA.

In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Treatment with DM-204 resulted in statistically significant lower mean differences compared to untreated animals after 21 days for the following parameters:

2.6% (p=0.0103) lower HbA1c levels at day 21
70% (p=0.0058) lower difference in fasting blood glucose levels
25 mm/Hg (p=0.0004) lower difference in systolic blood pressure levels
>20% (p=0.0156) improvement in total cholesterol levels

“These results are very encouraging and provide a strong foundation with which to move DM-204 forward,” said Dr. John Amatruda, DiaMedica’s Scientific Advisory Board member and former Senior Vice President and Franchise Head for Diabetes and Obesity at Merck Research Laboratories.

“DM-204 has the opportunity to fundamentally change the treatment regimen for Type 2 diabetes patients with hypertension and high cholesterol. DM-204 could potentially become the single long-acting treatment by virtue of being a monoclonal antibody therapy”," stated Dr. Mark Williams, Vice President, of Research at DiaMedica. “The chronic in vivo model data shows DM-204’s ability to prevent disease progression of Type 2 diabetes and increased blood pressure.”

Back

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe